Tempest Therapeutics, Inc. Common Stock
$0.97
Market Cap
$16.01M
Shares Outstanding
16.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jun 28, 2021
Round Lot
100
Locale
US
Day Open
$0.84
Day High
$1.09
Day Low
$0.84
Volume
4.80M
VWAP
$0.98
Prev Close
$0.90
Transactions
--
Acc. Volume
--
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
Tempest Therapeutics, Inc. Common Stock (TPST) closed the 2026-09-18 session at $0.97, up 8.16% versus the previous close (+0.07). The stock opened at $0.84 and traded between $0.84 and $1.09 during that session. Session trading volume was 4.8M shares. The volume-weighted average price (VWAP) is $0.98.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
Tempest Therapeutics, Inc. Common Stock has a market capitalization of $16.0 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. TPST is listed on the XNAS exchange. The company employs approximately 4 people. Tempest Therapeutics, Inc. Common Stock is headquartered in BRISBANE, CA. The recorded listing date is 2021-06-28.
On this page you can find market TPST stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.